Low Dose

ApprovedSmall molecule

Boehringer Ingelheim

Low Dose is one of 171 small molecule programs targeting Acute Myocardial Infarction. It is currently in Approved.

Indications

Total Trials

Active Trials

170

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

InfluenzaActive, not recruiting

ObesityActive, not recruiting

Diabetes Mellitus, Type 2Completed

Disc Degenerative DiseaseNot yet recruiting

Urinary Tract InfectionActive, not recruiting

Acute Myocardial InfarctionPhase 2

Active, not recruiting

InfluenzaPhase 1

Active, not recruiting

ObesityPhase 2

Active, not recruiting

Diabetes Mellitus, Type 2Approved

Completed

Disc Degenerative DiseasePreclinical

Not yet recruiting

Recruiting

Urinary Tract InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Low Dose

Boehringer Ingelheim

Approved

1 2

Fluzone

GSK

Preclinical

37 3

Crestor

AstraZeneca

Preclinical

1 4

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 5

COMIRNATY

Pfizer

Preclinical

1 6

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 7

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 8

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 9

Xuanfei Baidu Granule

PPeking University People's Hospital

Preclinical

1 10

RSV a Memphis 37

IImperial College London

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Age-Related Macular Degeneration

NCT07668804

Q4 2030

PreclinicalNot yet recruiting

Disc Degenerative Disease

NCT07668466

Clinical

Trials by Indication[1]

Double-blind1 trial

A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M

Completed·HHoly Stone Healthcare Co., Ltd·Phase 2·NCT02493712·51 enrolled

Urinary Tract Infection1 trial

Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

Suspended·XXiangbei Welman Pharmaceutical Co., Ltd·Phase 2·NCT01601093·288 enrolled

Acute Myocardial Infarction1 trial

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

Completed·BBeijing Northland Biotech. Co., Ltd.·Phase 2·NCT05485818·62 enrolled

Apnea of Prematurity1 trial

Apnea of Prematurity Results in Respiratory Distress and Cyanosis. Caffeine Citrate Can Treat It.

Active, not recruiting·NNishtar Medical University·Phase 1·NCT06905496·114 enrolled

Metabolism1 trial

Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01371006·29 enrolled

7 more indications

Safety and Efficacy1 trial

A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults

Completed·UUniversity of Missouri-Columbia·Phase 1/2·NCT00549523·133 enrolled

Obesity1 trial

Dose-ranging Study of SKF7™ for Obesity

Completed·IIndonesia University·Phase 2·NCT04557267·160 enrolled

Feeding Intolerance1 trial

Multi-Center Study of Different Doses Domperidone in Feeding Intolerance

Completed·NNanfang Hospital, Southern Medical University·Phase 4·NCT02980250·118 enrolled

Influenza1 trial

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Completed·KKBio Inc·Phase 1·NCT04439695·120 enrolled

Diabetes Mellitus, Type 21 trial

THE EFFECT OF LUMBRICUS RUBELLUS DLBS1033 EXTRACT ON LEVELS OF HIGH-SENSITIVITY C-REACTIVE PROTEIN, VASCULAR ENDOTHELIAL GROWTH FACTOR, AND QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Completed·UUniversitas Sebelas Maret·Approved·NCT07684625·60 enrolled

Age-Related Macular Degeneration1 trial

A Phase I/IIa Trial to Evaluate the Safety, Tolerability and Efficacy After Single Administration of TO-O-1007 (Intravitreal Implant) in Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Recruiting·TTheratocular Biotek Co.·Preclinical·NCT07668804·31 enrolled

Disc Degenerative Disease1 trial

A Phase I/II, Open-label, Single Administration Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration

Not yet recruiting·CCartago Biotech Pty Ltd·Preclinical·NCT07668466·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Low Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

Low Dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2030

Trials by Indication[1]

Double-blind1 trial

Urinary Tract Infection1 trial

Acute Myocardial Infarction1 trial

Apnea of Prematurity1 trial

Metabolism1 trial

Safety and Efficacy1 trial

Obesity1 trial

Feeding Intolerance1 trial

Influenza1 trial

Diabetes Mellitus, Type 21 trial

Age-Related Macular Degeneration1 trial

Disc Degenerative Disease1 trial

References

Drug Info

Quick Facts

Related News